Bevacizumab, an anti-VEGFA mAb, was approved for colorectal cancer treatment in 2004 and has been approved for glioblastoma, non-small-cell lung carcinoma (NSCLC), kidney, cervical, and ovarian cancers to date [100]. The gene discussed is VEGFA; the disease is non-small cell lung carcinoma.